2012, Volume 6, Issue 2
Frontiers of Medicine >> 2012, Volume 6, Issue 2 doi: 10.1007/s11684-012-0191-9
The biopharmaceutical industry in China: history and future perspectives
National Institutes for Food and Drug Control, Beijing 100050, China
Next Previous
Abstract
Biopharmaceuticals reflect the rapid progress achieved in modern biomedical research. This area has also become one of the main criteria for assessing the development level of biotechnology for a particular country. Although it has been only three decades since the first biopharmaceutical, recombinant human insulin, was licensed by the US Food and Drug Administration, the biopharmaceutical industry has become the fastest growing, most dynamic and technology-intensive sector in the biomedical field. Since the licensing of recombinant human interferon α1b in 1989, the biopharmaceutical industry in China has gone through initial developments and gradually entered a period of rapid growth. This paper provides an overview of the status and development trends of biopharmaceuticals in China, and compares them with those observed in developed countries.
Keywords
biopharmaceuticals ; antibodies ; market trends ; diseases ; China ; national regulatory agency
京公网安备 11010502051620号
